Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (8): 937-946.doi: 10.12092/j.issn.1009-2501.2024.08.011

Previous Articles     Next Articles

Advances in clinical research of CAR-T immunotherapy for systemic rheumatic diseases

LI Zhi1, ZHANG Mengying2, ZHU Chuanmiao1, MAO Li1, PENG Hui3   

  1. 1 Department of Rheumatology, 2 Central Laboratory, 3 Office of science and technology administration, The First Affiliated Hospital of Wannan Medical College, Wuhu 241001, Anhui, China
  • Received:2024-03-08 Revised:2024-03-20 Online:2024-08-26 Published:2024-07-17

Abstract:

Systemic rheumatic disease is a kind of autoimmune disease which is caused by the dysfunction of autoimmune cells and the damage of multiple systems and organs. Traditional immunosuppressants play an important role in the treatment of systemic rheumatic diseases, but there are still a considerable number of refractory systemic rheumatic diseases that do not respond well to traditional immunosuppressant therapy, and new therapeutic methods need to be explored. Chimeric antigen receptor T cell therapy (CAR-T) immunotherapy was initially used for the treatment of malignant hematological diseases and has shown good efficacy. Recently,CAR-T immunotherapy has also achieved remarkable efficacy in refractory systemic lupus erythematosus. It brings new hope for the treatment of systemic rheumatic diseases. This article summarizes the progress of clinical application of CAR-T immunotherapy in systemic rheumatic diseases in recent years, aiming to enhance clinicians' cognition of CAR-T immunotherapy and promote the further development of CAR-T immunotherapy in systemic rheumatic diseases.

Key words: CAR-T, rheumatic disease, systemic lupus erythematosus, sjogren syndrome

CLC Number: